Suppr超能文献

成人克隆性肥大细胞疾病的生物学现状和诊断。

Current state of biology and diagnosis of clonal mast cell diseases in adults.

机构信息

Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.

出版信息

Int J Lab Hematol. 2012 Oct;34(5):445-60. doi: 10.1111/j.1751-553X.2012.01427.x. Epub 2012 May 3.

Abstract

Mastocytosis comprises a heterogeneous group of disorders characterized by the presence of clonal mast cells (MC) in organs such as skin, bone marrow (BM), and gastrointestinal tract, among other tissues. The clonal nature of the disease can be established in most adult patients by the demonstration of activating KIT mutations in their BM MC. When highly sensitive techniques capable of identifying cells present at very low frequencies in a sample are applied, BM MC from virtually all systemic mastocytosis patients display unique immunophenotypical features, particularly the aberrant expression of CD25. By contrast, large, multifocal BM MC aggregates (the only World Health Organization major criterion for systemic mastocytosis) are absent in a significant proportion of patients fulfilling at least three minor criteria for systemic mastocytosis, particularly in subjects studied at early stages of the disease with very low MC burden. Moreover, recent molecular and immunophenotypical investigations of BM MC from patients with indolent systemic mastocytosis have revealed a close association of some biological features (e.g., multilineage involvement of hematopoiesis by the KIT mutation and an immature mast cell immunophenotype) with an increased risk for disease progression. These observations support the fact that, although the current consensus diagnostic criteria for systemic mastocytosis have been a major advance for the diagnosis and classification of the disease, rationale usage of the most sensitive diagnostic techniques available nowadays is needed to improve the diagnosis, refine the classification, and reach objective prognostic stratification of adult mastocytosis.

摘要

肥大细胞增多症包括一组异质性疾病,其特征是在皮肤、骨髓(BM)、胃肠道等组织中存在克隆性肥大细胞(MC)。大多数成年患者的疾病克隆性质可以通过在其 BM MC 中证明激活的 KIT 突变来确立。当应用能够识别样品中存在的极低频率细胞的高度敏感技术时,几乎所有系统性肥大细胞增多症患者的 BM MC 都显示出独特的免疫表型特征,特别是 CD25 的异常表达。相比之下,在满足系统性肥大细胞增多症至少三个次要标准的患者中,存在大量、多灶性 BM MC 聚集(系统性肥大细胞增多症的唯一世界卫生组织主要标准)的比例显著降低,特别是在疾病早期研究时,MC 负担非常低的患者中。此外,最近对惰性系统性肥大细胞增多症患者的 BM MC 进行的分子和免疫表型研究表明,一些生物学特征(例如,KIT 突变导致造血多谱系受累和不成熟的肥大细胞免疫表型)与疾病进展的风险增加密切相关。这些观察结果支持这样一个事实,即尽管目前用于系统性肥大细胞增多症的诊断和分类的共识诊断标准是一个重大进展,但需要合理使用当今最敏感的诊断技术来改善诊断、完善分类,并实现成人肥大细胞增多症的客观预后分层。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验